Skip to content
Lawsuits.

EU Commission: Illumina/GRAIL prohibition antitrust case

European Commission · M.10188 · decided Sep 6, 2022 · Dismissed

Decision

The Commission blocked Illumina's acquisition of cancer test developer GRAIL, finding it would stifle innovation in blood-based early cancer detection.

The case

Against
Illumina, GRAIL
Regulator
European Commission
Docket
M.10188
Decided
Sep 6, 2022
Status
DismissedThe Court of Justice ruled in September 2024 that the Commission lacked jurisdiction under the Article 22 referral policy; the Commission withdrew its decisions.
Outcome
The Commission prohibited Illumina's already-completed acquisition of GRAIL; the decision fell after the Court of Justice ruling on jurisdiction.

History

1 dated entry
DateEntry
Sep 6, 2022Decision: EU Commission: Illumina/GRAIL prohibition

Related cases

WhenCase
Sep 25Telephone Conference Todaynext dateUnited States v. Visa (debit)Telephone ConferenceActiveAntitrustS.D. N.Y.
Oct 2Joint proposed final judgment due in 7dnext dateUnited States v. Google (ad tech)Joint proposed final judgment dueDecidedAntitrustE.D. Va.
Jul 23Filed 64d agofiledEU Commission: Google DMA finesDecidedAntitrustEuropean CommissionEUR 890 million
Jul 9Filed 78d agofiledEU Commission: SAP ERP support commitmentsClosedAntitrustEuropean Commission
Jun 25Filed 92d agofiledEU Commission: AWS and Azure DMA cloud investigationActiveAntitrustEuropean Commission
Jun 9Filed 4mo agofiledEU Commission: Meta WhatsApp AI interim measuresActiveAntitrustEuropean Commission
May 14Filed 4mo agofiledCMA: Microsoft business software SMS investigationActiveAntitrustUK CMA
Feb 5Filed 8mo agofiledBundeskartellamt: Amazon price control prohibitionDecidedAntitrustBundeskartellamtEUR 59 million
Caption and links

Illumina / GRAIL

Lawsuit updates by email

Tuesdays, only in weeks with rulings, filings or hearings in data and AI cases.

Double opt-in. Unsubscribe any time.